Caesarean section · women with a previous caesarean section, a live singleton fetus (37‐42 weeks of gestation) in cephalic presentation and a reactive…
It is very uncertain whether vaginal PGE2 pessary changes caesarean section compared with vaginal PGE2 tablet (very low certainty).
1 finding from 1 review
Serious neonatal morbidity or perinatal death · women with a previous caesarean section, a live singleton fetus (37‐42 weeks of gestation) in cephalic presentation and a reactive…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious maternal morbidity or death · women with a previous caesarean section, a live singleton fetus (37‐42 weeks of gestation) in cephalic presentation and a reactive…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vaginal birth · women with singleton cephalic fetuses undergoing assessment for pre‐induction cervical ripening.
Bishop score showed no clear difference in vaginal birth compared with transvaginal ultrasound (moderate certainty).
1 finding from 1 review
Caesarean section · women with singleton cephalic fetuses undergoing assessment for pre‐induction cervical ripening.
Bishop score showed no clear difference in caesarean delivery compared with transvaginal ultrasound (moderate certainty).
1 finding from 1 review
Neonatal admission to NICU · women with singleton cephalic fetuses undergoing assessment for pre‐induction cervical ripening.
Bishop score showed no clear difference in neonatal admission to NICU compared with transvaginal ultrasound (moderate certainty).
1 finding from 1 review
Need of misoprostol for cervical ripening · women with singleton cephalic fetuses undergoing assessment for pre‐induction cervical ripening.
Bishop score probably leads to lower need of misoprostol for cervical ripening compared with transvaginal ultrasound (moderate certainty).
1 finding from 1 review
Meconium staining of amniotic fluid · women with singleton cephalic fetuses undergoing assessment for pre‐induction cervical ripening.
Bishop score showed no clear difference in meconium staining of amniotic fluid compared with transvaginal ultrasound (moderate certainty).
1 finding from 1 review
Apgar score less than 7 at 5 minutes · women with singleton cephalic fetuses undergoing assessment for pre‐induction cervical ripening.
Bishop score showed no clear difference in apgar score at 5 minutes less than 7 compared with transvaginal ultrasound (moderate certainty).
1 finding from 1 review
Death or cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death or cerebral palsy (up to school age)** compared with placebo (outcomes (low certainty).
2 findings from 1 review
Major neurodevelopmental disability at childhood · women at risk of preterm birth (< 34 weeks' gestation)
It is very uncertain whether magnesium sulphate changes major neurodevelopmental disability (school age)** compared with placebo (outcomes (very low certainty).
1 finding from 1 review
Death or major neurodevelopmental disability · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death or major neurodevelopmental disability (up to school age)** compared with placebo (outcomes (low certainty).
2 findings from 1 review
Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in severe maternal outcome potentially related to treatment (death,… compared with placebo (outcomes (low certainty).
1 finding from 1 review
Adverse effects sufficient to stop treatment · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate probably leads to higher adverse effects severe enough to stop treatment** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Caesarean section · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in mode of birth (caesarean section)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Postpartum haemorrhage · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in postpartum haemorrhage** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Any breastfeeding at hospital discharge · women at risk of preterm birth (< 34 weeks' gestation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Women’s views of treatment** · women at risk of preterm birth (< 34 weeks' gestation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate leads to lower cerebral palsy (up to 2 years' corrected age)** compared with placebo (outcomes (high certainty).
2 findings from 1 review
Major disability by 18 to 24 months corrected age (aligned definition) · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in major neurodevelopmental disability (up to 2 years' corrected age)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review